Daiwa Securities Group’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-530
| Closed | -$14K | – | 1182 |
|
|
2025
Q4 | $14K | Hold |
530
| – | – | ﹤0.01% | 1168 |
|
|
2025
Q3 | $11K | Sell |
530
-72
| -12% | -$1.7K | ﹤0.01% | 1152 |
|
|
2025
Q2 | $13K | Buy |
602
+53
| +10% | +$985 | ﹤0.01% | 1110 |
|
|
2025
Q1 | $9K | Hold |
549
| – | – | ﹤0.01% | 1100 |
|
|
2024
Q4 | $10K | Sell |
549
-92
| -14% | -$1.49K | ﹤0.01% | 1117 |
|
|
2024
Q3 | $10K | Buy |
641
+90
| +16% | +$1.5K | ﹤0.01% | 1127 |
|
|
2024
Q2 | $9K | Sell |
551
-100
| -15% | -$1.61K | ﹤0.01% | 1165 |
|
|
2024
Q1 | $12K | Hold |
651
| – | – | ﹤0.01% | 1156 |
|
|
2023
Q4 | $20K | Hold |
651
| – | – | ﹤0.01% | 1124 |
|
|
2023
Q3 | $14K | Hold |
651
| – | – | ﹤0.01% | 1111 |
|
|
2023
Q2 | $16K | Hold |
651
| – | – | ﹤0.01% | 1112 |
|
|
2023
Q1 | $12K | Hold |
651
| – | – | ﹤0.01% | 1098 |
|
|
2022
Q4 | $10K | Buy |
651
+182
| +39% | +$2.85K | ﹤0.01% | 1113 |
|
|
2022
Q3 | $8K | Hold |
469
| – | – | ﹤0.01% | 1137 |
|
|
2022
Q2 | $7K | Hold |
469
| – | – | ﹤0.01% | 1148 |
|
|
2022
Q1 | $11K | Hold |
469
| – | – | ﹤0.01% | 1130 |
|
|
2021
Q4 | $11K | Sell |
469
-81
| -15% | -$1.63K | ﹤0.01% | 1143 |
|
|
2021
Q3 | $9K | Buy |
550
+233
| +74% | +$4.49K | ﹤0.01% | 1145 |
|
|
2021
Q2 | $8K | Hold |
317
| – | – | ﹤0.01% | 1050 |
|
|
2021
Q1 | $8K | Buy |
317
+18
| +6% | +$792 | ﹤0.01% | 1051 |
|
|
2020
Q4 | $16K | Sell |
299
-590
| -66% | -$29.3K | ﹤0.01% | 990 |
|
|
2020
Q3 | $37K | Buy |
889
+20
| +2% | +$864 | ﹤0.01% | 955 |
|
|
2020
Q2 | $37K | Hold |
869
| – | – | ﹤0.01% | 921 |
|
|
2020
Q1 | $37K | Hold |
869
| – | – | ﹤0.01% | 971 |
|
|
2019
Q4 | $37K | Sell |
869
-46
| -5% | -$2K | ﹤0.01% | 978 |
|
|
2019
Q3 | $33K | Hold |
915
| – | – | ﹤0.01% | 973 |
|
|
2019
Q2 | $24K | Hold |
915
| – | – | ﹤0.01% | 998 |
|
|
2019
Q1 | $25K | Sell |
915
-37,773
| -98% | -$882K | ﹤0.01% | 980 |
|
|
2018
Q4 | $625K | Sell |
38,688
-3,213
| -8% | -$62.4K | 0.01% | 540 |
|
|
2018
Q3 | $870K | Sell |
41,901
-15,105
| -26% | -$238K | 0.01% | 524 |
|
|
2018
Q2 | $870K | Sell |
57,006
-16,289
| -22% | -$290K | 0.01% | 509 |
|
|
2018
Q1 | $1.65M | Buy |
73,295
+1,447
| +2% | +$40.1K | 0.01% | 407 |
|
|
2017
Q4 | $2.16M | Buy |
+71,848
| New | +$2.3M | 0.02% | 369 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Daiwa Securities Group's ACAD Position: Q1 2026 in Review
Daiwa Securities Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 530 shares — an estimated $14K sold.
Daiwa Securities Group first reported a position in ACAD in Q4 2017 and held it in 33 quarters. The position peaked at $2.16M in Q4 2017. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Daiwa Securities Group reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Daiwa Securities Group sold 530 Acadia Pharmaceuticals shares in Q1 2026, an estimated $14K.
- Daiwa Securities Group first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 33 quarters.
- Daiwa Securities Group's Acadia Pharmaceuticals position peaked at $2.16M in Q4 2017.
- 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.